Sentynl Therapeutics

Private

#Rare Disease #Neurology #Menkes Disease

Specialty pharmaceutical company focused on rare disease therapies. Develops and commercializes treatments for rare and ultra-rare diseases, including CUTX-101 (copper histidinate) for Menkes disease.

Company Info

Sector:Rare Disease / Specialty Pharma

Headquarters:San Diego, California, USA

Founded:2015

Website:sentynl.com/

Upcoming Milestones & Key Dates

2026

Business

Mereo deal completion expected

2026

Commercial

CUTX-101 lifecycle management updates

Clinical Development Pipeline

CUTX-101

Target: Copper histidinate replacement

Menkes disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Naloxone (partnered)

Target: Opioid receptor antagonist

Opioid overdose

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Leadership Team

Matt Heck

Founder & Chief Executive Officer

Michael Hercz

EVP, Chief Legal & Compliance Officer

Jennifer Reese

SVP Medical Affairs

Careers & Job Openings

See all open roles

Apply Now →